3T Biosciences

3T Biosciences is a private, clinical-stage biotech based in South San Francisco, founded in 2015. The company's core innovation is the 3T-TRACE platform, which integrates high-diversity experimental libraries with machine learning to discover novel tumor targets and design TCR-based therapeutics, addressing a major bottleneck in solid tumor treatment. With a pipeline advancing toward first-in-human studies, the company is building its clinical operations team and positioning itself in the competitive cell therapy space. Key risks include platform validation, clinical execution, and competition from established players and other novel modalities.

3T-TRACE (T-Cell Receptor Recognition and Antigen Characterization Engine): A proprietary platform combining high-diversity experimental libraries with machine learning to systematically identify novel tumor-specific pHLA targets and engineer selective TCR-derived therapeutics.

3T operates in the highly competitive TCR and T-cell engager space, competing with established players like Immunocore (FDA-approved) and Adaptimmune, as well as numerous private biotechs. Differentiation relies on the novelty and specificity of its platform-discovered targets and the potency of its therapeutic candidates.